Hemostatic markers are associated with the risk and prognosis of atrial fibrillation: The ARIC study by Alonso, Alvaro et al.
Hemostatic markers are associated with the risk and prognosis
of atrial fibrillation: the ARIC study
Alvaro Alonso, MD, PhD1, Weihong Tang, MD, PhD1, Sunil K. Agarwal, MD2, Elsayed Z.
Soliman, MD, MS3, Alanna M. Chamberlain, PhD1, and Aaron R. Folsom, MD, MPH1
1Division of Epidemiology and Community Health, School of Public Health, University of
Minnesota, Minneapolis, MN
2Department of Epidemiology, Gillings School of Global Public Health, University of North
Carolina, Chapel Hill, NC
3Department of Epidemiology, Division of Public Health Sciences, Wake Forest University School
of Medicine, Winston-Salem, NC
Abstract
Background—Various hemostatic markers are associated with the risk of cardiovascular
disease; however, limited information exists on their relationship with the occurrence and
prognosis of atrial fibrillation (AF).
Objectives—To assess whether hemostatic markers are associated with the incidence and
prognosis of AF.
Methods—We studied 14,858 men and women in the Atherosclerosis Risk in Communities
cohort, aged 45–64 and free of AF at baseline (1987–1989). Fibrinogen, von Willebrand factor
(vWf), factor VII activity (VIIc), factor VIII activity (VIIIc), protein C, antithrombin III (ATIII),
and activated partial thromboplastin time (aPTT) were measured in blood samples at baseline. AF
and other cardiovascular outcomes through 2005 were determined following standardized
protocols.
Results—During a median follow-up of 16.8 years, 1209 cases of AF were identified. In
multivariable Cox models, the hazard ratios (HR) and 95% confidence intervals (CI) of incident
AF associated with a 1-standard deviation (SD) increase in each marker were 1.13 (1.07–1.20) for
fibrinogen, 1.17 (1.11–1.23) for vWf, 1.17 (1.11–1.24) for factor VIIIc, 0.93 (0.88–1.00) for factor
VIIc, 0.98 (0.92–1.04) for protein C, 1.00 (0.94–1.06) for aPTT and 1.00 (0.95–1.06) for ATIII.
Greater factor VIIIc, fibrinogen and vWf were consistently associated with a higher risk of
cardiovascular outcomes and mortality in those with and without incident AF, while greater
protein C was associated with a lower risk of ischemic stroke.
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Conclusion—Several hemostatic markers are associated with the incidence of AF independently
of other cardiovascular risk factors. Their role in the risk stratification of AF patients should be
further studied.
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INTRODUCTION
Atrial fibrillation (AF), the most common cardiac arrhythmia in clinical practice, is expected
to affect more than 12 million Americans by 2050.1 Though our knowledge of the etiology
of AF is limited, previous research has described a number of risk factors and predictors of
incident AF in the general population, including traditional cardiovascular risk factors and
novel biomarkers, such as C-reactive protein or natriuretic peptides.2–4 Different lines of
evidence suggest that markers of hemostatic function could also be associated with the new
onset of AF. For instance, risk of coronary heart disease, an established risk factor for AF, is
higher in individuals with higher levels of von Willebrand factor and fibrinogen.5, 6 Also,
individuals with paroxysmal episodes of AF, some of them clinically undetected, might
experience changes in blood levels of hemostatic markers,7 which in turn could predict the
clinical diagnosis of AF. Finally, some hemostatic markers reflect other pathophysiological
processes. Fibrinogen and von Willebrand factor are markers of inflammation and
endothelial dysfunction, respectively. Both pathophysiological pathways might increase AF
risk, directly or through an elevated risk of overall cardiovascular disease.5, 8 Alternatively,
activated protein C has anti-inflammatory and anti-apoptotic effects, and stabilizes the
endothelial barrier,9 mechanisms that could prevent the development of the AF substrate.8,
10 Among hemostatic markers, fibrinogen was associated with AF risk in the Copenhagen
City Heart Study,11 but not in the Framingham Offspring Study.12 In addition, the later
study did not find associations of D-dimer or plasminogen activator inhibitor type 1 with AF
risk, but the number of AF events was limited.12
Individuals with AF have an increased risk of stroke and overall mortality.13 Stroke is a
severe and frequent complication of AF, facilitated by the lack of efficient atrial contraction
and consequent increased thrombogenesis.14 Therefore, markers of hemostasis might predict
the future risk of thromboembolic complications in AF patients, but support for this
hypothesis is limited to studies with relatively small sample sizes and short follow-up.15–17
Available evidence, thus, suggests that markers of hemostatic function could be related to an
increased risk of AF. To evaluate this question, we studied the association of hemostatic
markers with the incidence of AF in a large population-based cohort in the United States. As
a secondary aim, we explored whether hemostatic markers predicted differently the risk of
stroke, cardiovascular disease or mortality in individuals with and without incident AF.
METHODS
Study population
The Atherosclerosis Risk in Communities (ARIC) cohort is a large prospective study aimed
to identify risk factors of atherosclerosis and cardiovascular disease. A detailed description
of the ARIC cohort can be found elsewhere.18 Briefly, 15,792 men and women aged 45–64
from four communities in the United States (Jackson, Mississippi; Forsyth County, North
Carolina; Washington County, Maryland; suburbs of Minneapolis, Minnesota) were
recruited and examined in 1987–1989. The Jackson site recruited only African-Americans.
The racial composition of the cohort in the other three field centers reflected the underlying
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population, mostly whites in the Minneapolis and Washington County sites, and whites and
African-Americans in Forsyth County. Study participants were re-examined in three follow-
up visits, each three years apart. Additionally, they have been contacted by phone every year
since baseline. More than 90% of the surviving cohort continues to respond to the annual
follow-up phone calls. Institutional Review Boards at all participating institutions approved
the ARIC study. All study participants provided written informed consent.
For this analysis, we excluded individuals with prevalent AF at baseline, determined by
electrocardiogram (ECG) (n=37), those with unreadable or no ECG at baseline (n=310),
those taking anticoagulant therapy (n=90), and those without hemostatic markers
information (n=265) or missing information for other covariates (n=390). Additionally, we
excluded a small group of nonwhites in the Minnesota and Washington County sites and
those not white or African-American in the Forsyth County site (n=103). After applying
exclusion criteria, 14,858 participants were eligible for the follow-up.
Measurement of hemostatic markers
Blood was collected at baseline after an 8-hour fasting period. Samples were processed
following a standardized protocol and stored at −70°C for a few weeks until assayed.
Detailed methods for blood processing and measurement of hemostatic markers have been
published previously.19, 20 Fibrinogen was measured by the thrombin-time titration method;
factor VII activity (VIIc) and factor VIII activity (VIIIc) by clotting assays; von Willebrand
factor antigen and protein C antigen by ELISA; antithrombin III (ATIII) activity by a
chromogenic substrate method; and activated partial thromboplastin time (aPTT) on an
automated coagulometer. Reliability coefficients obtained from repeated testing on a sample
of subjects over several weeks were 0.72 for fibrinogen, 0.78 for factor VIIc, 0.86 for factor
VIIIc, 0.68 for von Willebrand factor, 0.56 for protein C, 0.42 for ATIII, and 0.92 for aPTT.
21
Ascertainment of atrial fibrillation and other cardiovascular events
AF in ARIC was ascertained from three different sources: ECGs performed at baseline and
at each follow-up visit; hospital discharge codes; and death certificates.22, 23 During each
study visit, a standard supine 12-lead resting ECG recording was done with MAC PC
Personal Cardiographs, and transmitted to the ARIC Central ECG Reading Center for
coding, interpretation, and storage. ECG recordings automatically coded as AF were
visually re-checked by a cardiologist.24 Additionally, all hospitalization discharges and
death certificates from baseline through December 2005 including an ICD code for AF
(ICD-9: 427.31 or 427.32, ICD-10: I48) were considered events. Validity of hospital
discharge codes is close to 90% in the ARIC cohort,22 and almost 100% in other similar
settings.25 Individuals with atrial flutter were classified as AF cases. Episodes of AF
occurring in the context of cardiac surgery were not considered events.
New stroke and coronary heart disease events during the follow-up were ascertained
according to published methodology.26, 27 Cohort participants are contacted annually by
phone and interviewed about hospitalizations in the previous year. Trained abstractors
collected information on all hospitalizations involving stroke or cardiovascular disease.
Mortality was ascertained through annual phone calls, ongoing surveillance of health
department death certificate files, search of hospital records, and the National Death Index.
Death certificates were also reviewed to identify additional cases of cardiovascular disease.
Events were classified following expert review and the application of standard criteria. For
the purpose of this analysis, a coronary heart disease (CHD) event was defined as a definite
or probable hospitalized myocardial infarction or a definite coronary heart disease death,
while ischemic stroke was defined as any definite or probable ischemic stroke episode.26, 27
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Assessment of other variables
At baseline, study participants completed questionnaires collecting information on their
medical history, education, income, use of medication, smoking, and alcohol intake. Sports-
related physical activity was assessed by the Baecke questionnaire.28 Weight and height
were measured by trained technicians following a standardized protocol, with the participant
wearing a light scrub and no shoes. Sitting blood pressure was taken 3 times with a random
zero sphygmomanometer, with the average of the 2 last measurements considered the
participant's blood pressure. Blood cholesterol and glucose were measured according to
standardized methods.18
Statistical analysis
The association of hemostatic markers with the risk of incident AF was estimated with a
Cox proportional hazards model with time to AF as the main independent variable. Follow-
up time was calculated as the time elapsed between the baseline visit to the first diagnosis of
AF, death or December 31, 2005, whichever occurred earlier. Models were run for each
hemostatic marker separately. In an initial model, we included the hemostatic marker
(categorized in quartiles, calculated from the entire eligible sample), age, race and sex. In a
second model, we added potential confounders for this association: body mass index
(continuous), height (continuous), education (categorical), income (categorical), study site
(categorical), cigarette smoking (current, past, or never smoking), alcohol intake
(continuous), sports-related physical activity (continuous), systolic blood pressure
(continuous), use of antihypertensive medication (categorical), diabetes (categorical), total
cholesterol (continuous), HDL cholesterol (continuous), use of lipid-lowering medication
(categorical), and ECG-based left ventricular hypertrophy (categorical). Finally, in a third
model, we additionally adjusted for prevalence of heart failure and myocardial infarction at
baseline, as potential mediators of the association between hemostatic markers and AF risk.
We repeated these analyses including the hemostatic markers as a continuous variable and
estimated the hazard ratio (HR) of AF associated with a difference of 1 standard deviation
(SD) in the marker. In separate analyses, we categorized hemostatic markers using the
percentiles 90th and 95th (or 5th and 10th for factors showing inverse associations with AF).
We additionally estimated the joint association of fibrinogen and von Willebrand factor, and
of factor VIIIc and von Willebrand factor with the incidence of AF creating 9 categories of
exposure based on cross-classification by tertiles of these hemostatic markers. Finally, we
conducted analyses stratified by gender, age (≥55, <55), race, and prevalence of CVD at
baseline. The proportionality of the hazards was tested adding to the model an interaction
term between follow-up time and exposure of interest.
We carried out several sensitivity analyses to evaluate the robustness of our results to
changes in the AF definition. First, we repeated the analysis including only cases of AF
identified from ECGs done during the three follow-up visits. Second, we estimated the risk
of AF censoring a participant if she or he was hospitalized with a definite or probable
myocardial infarction. Third, we excluded individuals who developed AF in the first 5 years
of follow-up, to avoid including cases with prevalent but undetected paroxysmal AF at
baseline.
Finally, we determined whether associations of hemostatic markers with risk of stroke,
coronary heart disease and mortality were similar in individuals with or without AF. To this
purpose, we selected ARIC participants free of stroke, myocardial infarction, heart failure
and AF at baseline, adding incidence of AF as a time-varying exposure in Cox models and
adjusting for potential confounders measured at baseline. Three separate sets of analyses
were conducted, using three different outcomes: ischemic stroke, CHD, and death. As with
the primary analysis, follow-up was defined as the time elapsed since baseline to the event
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of interest, death, or December 31, 2005. Initial models were adjusted for age at baseline,
gender and race. Subsequent analyses were adjusted for the same variables included in
multivariate analyses described above.
RESULTS
Table 1 reports baseline characteristics of the 14,858 participants according to race and
incidence of AF. Compared to those who did not develop AF during the follow-up, those
who did were older, more likely to be men, smokers, hypertensive, or diabetic, and had
higher body mass index and higher levels of von Willebrand factor, fibrinogen and factor
VIIIc. Additionally, they were more likely to have a history of myocardial infarction or heart
failure.
During a median follow-up of 16.8 years (percentile 25th 16.0, percentile 75th 17.7), 1209
new cases of AF were identified. The main source of case ascertainment was hospital
discharge codes (93.9%), followed by ECGs at study visits (9.6%), with only a small
number identified through death certificates (0.6%). One hundred and five cases (8.4%)
were identified through more than 1 source.
AF incidence was strongly associated with several hemostatic markers (table 2). Individuals
with higher levels of fibrinogen, factor VIIIc, and von Willebrand factor had higher risk of
AF, even after adjustment for a number of confounders and potential mediators, including
history of heart failure or myocardial infarction at baseline. Higher factor VIIc was
associated with a lower risk of AF, but only in multivariable models. Results were very
similar when we excluded AF incident cases occurring in the first 5 years of follow-up
(n=184) (data not shown). Table 3 presents results comparing AF risk among those with
extreme values (defined as ≥90th percentile or ≥95th percentile for fibrinogen, factor VIIIc,
von Willebrand factor, aPTT and ATIII, and ≤5th or ≤10th percentile for protein C and
factor VIIc) compared to the rest of the sample. Results were similar to those obtained in the
quartile analysis. In addition, low levels of protein C (below the 5th percentile, ≤2.3 μg/mL)
were associated with a higher risk of AF (HR 1.33, 95% 1.07–1.65).
Von Willebrand factor was associated with AF incidence independently of fibrinogen
(figure 1A) and factor VIIIc (figure 1B). In multivariable models including von Willebrand
factor and fibrinogen simultaneously, HRs (95% CI) of AF associated with 1-SD increase
were 1.15 (1.09–1.21) for von Willebrand factor and 1.10 (1.04–1.17) for fibrinogen.
Corresponding HRs (95% CI) for AF in a model including von Willebrand factor and factor
VIIIc were 1.10 (1.02–1.19) and 1.10 (1.01–1.18), respectively. The associations of factor
VIIc and protein C with AF were also independent of each other even though both markers
were moderately correlated (r=0.41, p<0.0001). Adjusting for protein C levels and multiple
covariates, the HR (95% CI) of AF in those with factor VIIc ≤5th percentile compared to
those >5th percentile was 1.24 (0.96–1.60), while the corresponding HR for protein C
adjusting for factor VIIc levels was 1.30 (1.04–1.61).
The results did not appreciably change when follow-up was censored at the time a study
participant was hospitalized with a definite or probable myocardial infarction (supplement
table 1). In an analysis including only AF cases identified through ECGs done at follow-up
visits (n=116 cases), factor VIIc and protein C were inversely associated with the incidence
of AF, but no associations were found for other hemostatic markers (supplement table 2).
Analyses stratified by age, race, gender or baseline history of CVD provided overall similar
results (supplement table 3). The only exceptions were factor VIIc, which was inversely
associated with AF in young but not older individuals (HR, 95% CI, for 1-SD increase in
<55 year old participants 0.82, 0.73–0.92, and in ≥55 year old 0.99, 0.91–1.07, p for
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interaction=0.04) and von Willebrand factor, which was a stronger predictor of AF in
women than in men (HR, 95% CI, for 1-SD increase in women 1.26, 1.17–1.36, and in men
1.09, 1.01–1.18, p for interaction=0.007).
Finally, we assessed whether hemostatic markers were similarly associated with incidence
of ischemic stroke, CHD, or total mortality in those who developed AF prior to
cardiovascular events during the follow-up and those who did not. In an analysis including
AF incidence as a time-varying exposure and stratifying by AF incidence, hemostatic
markers presented similar associations in both groups (table 4). From 585 incident ischemic
strokes, 1218 CHD events, and 2398 deaths, 55, 70 and 318 respectively occurred after AF
incidence. Greater factor VIIIc, fibrinogen and von Willebrand factor at baseline were
consistently associated with a higher risk of cardiovascular outcomes and mortality in
individuals with and without incident AF, while protein C was associated with an inverse
risk of ischemic stroke. No clear associations were observed for aPTT, ATIII and factor
VIIc (table 4).
DISCUSSION
In this ethnically diverse, middle-aged population, higher levels of fibrinogen, factor VIIIc,
and von Willebrand factor were associated with a higher risk of incident AF, while protein C
and factor VIIc were associated inversely with AF incidence. In addition, all of these except
factor VIIc were similarly associated with the risk of stroke, coronary heart disease and
overall mortality in individuals with and without AF.
Ours is the first prospective study to report the association of a large panel of hemostatic
markers and the risk of AF. Two previous publications explored whether fibrinogen was
related to the risk of AF, with inconsistent results. In the Copenhagen City Heart Study,
which identified 286 AF cases in 8870 participants, the HR (95% CI) of AF in the highest
versus the lowest quartile of fibrinogen was 2.07 (1.29–3.32).11 However, in an analysis of
3120 participants of the Framingham Offspring Study, including 209 incident cases of AF,
fibrinogen was not associated with the incidence of AF (HR, 95% C 1.09, 95% CI 0.94–
1.26, for 1-SD increment).12 The later study did not find associations of D-dimer or
plasminogen activator inhibitor type 1 with AF risk.12
Different mechanisms could explain the association of hemostatic markers with higher AF
risk. Fibrinogen is a known marker of inflammation, a potential pathogenic pathway
potentially leading to AF.8 Similarly, elevated von Willebrand factor is considered a marker
of endothelial dysfunction,29 which leads to oxidative stress, inflammation and
atherosclerosis,30 indirectly predisposing to AF. Von Willebrand factor, also, has been
associated with some risk factors for AF, such as diabetes.31 The association of AF risk with
factor VIIIc could be due to the strong correlation between the latter and von Willebrand
factor levels.
Low levels of protein C and factor VIIc were associated with increased incidence of AF.
Protein C is an anti-thrombotic factor, but also has anti-inflammatory and anti-apoptotic
effects, mediated by the protein-activated receptor-1 (PAR-1) signaling pathway.9 Protein C,
through these mechanisms, could prevent the development of atrial fibrosis, the substrate for
AF. It is unclear, however, how factor VIIc could be associated with lower risk of AF.
Factor VII, like protein C, is a ligand for the endothelial protein C receptor (EPCR)32 but, in
contrast to protein C, factor VII binding to EPCR does not activate the PAR-1 pathway,33
and has an overall procoagulant effect.
Reverse causation bias might explain our observations. Undiagnosed paroxysmal AF in
ARIC participants at baseline could create a prothrombotic state,14 with higher levels of
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markers such as fibrinogen and von Willebrand factor,34 or lower protein C. However, an
analysis excluding AF cases identified in the first 5 years of follow-up—more likely to have
undetected prevalent paroxysmal AF—provided comparable results.
Previous studies have reported associations of fibrinogen, factor VIIIc, von Willebrand
factor, and protein C with incidence of stroke and CHD in the general population.5, 35, 36
Similar evidence for individuals with AF is limited to relatively small studies or with short
follow-up, but still indicative of a relation between hemostatic markers and cardiovascular
outcomes in AF patients.15, 16 Our results further suggest that these associations equally
apply to individuals with and without AF. A major caveat in our analysis, however, is that
hemostatic markers were measured at baseline, in many cases years before the clinical
diagnosis of AF.
The present analysis has notable strengths, including the large sample, long follow-up, and
detailed information on cardiovascular risk factors and events. Some limitations, however,
affect our study. First, most AF cases were identified through hospital discharge codes. We
and others have shown adequate specificity of hospital discharge codes of AF,22, 25 but
cases identified and treated only in outpatient settings were probably missed. Additional
indirect evidence of the validity of AF ascertainment in the ARIC study includes the similar
incidence rates of AF in our cohort compared to other populations,22 and the strong and
specific association of genetic variants in the 4q25 chromosomal region with the risk of AF
in ARIC.37 Second, hemostatic markers were measured only once at baseline, introducing
potential nondifferential measurement error in the exposure variables. Third, unmeasured or
residual confounding could partly explain the results. For example, data on well-established
biomarkers of AF such as C-reactive protein or natriuretic peptides3, 38 were not available in
the ARIC cohort at baseline. Finally, we only assessed the association of AF with markers of
hemostatic function available in the entire ARIC cohort.
In conclusion, we have shown that certain markers of hemostatic function, including
fibrinogen, von Willebrand factor, factor VIIIc, protein C, and factor VIIc are associated
with new-onset of AF independent of known risk factors for AF. Additionally, our results
suggest that hemostatic markers might be useful in the risk assessment of patients with AF.
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tertiles of von Willebrand factor and factor VIII activity (FVIIIc) (B), ARIC, 1987–2005.
Cox proportional hazards model adjusted for age, race, gender, center, education, income,
smoking, alcohol intake, sports-related physical activity, body mass index, height, left
ventricular hypertrophy, systolic blood pressure, use of antihypertensive medications,
diabetes, cholesterol meds, HDL-cholesterol, total cholesterol, and history of myocardial
infarction or heart failure at baseline.
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Table 1
Baseline characteristics of study participants by race and atrial fibrillation incidence during follow-up, ARIC,
1987–1989
Whites African-Americans
No AF AF No AF AF
N 10131 976 3518 233
Age, years 54.1 (5.7) 57.3 (5.3) 53.4 (5.8) 56.2 (5.7)
Women 53.9 41.5 62.2 55.4
Education
 Less than high school 16.3 24.9 40.3 51.5
 High school degree 45.8 42.7 28.7 27.0
 College 37.9 32.4 31.0 21.5
Body mass index, kg/m2 26.9 (4.8) 28.4 (5.6) 29.5 (6.1) 31.2 (6.8)
Smoking
 Never 41.0 30.8 46.0 42.9
 Former 34.8 39.9 24.2 22.8
 Current 24.2 29.3 29.8 34.3
Alcohol, g/week 45.4 (93.1) 50.4 (103.1) 33.0 (100.0) 27.2 (76.9)
Sports-related physical activity 2.5 (0.8) 2.5 (0.8) 2.2 (0.7) 2.1 (0.6)
Hypertension 25.4 44.3 54.3 73.0
Diabetes 8.4 15.7 18.2 33.9
Left ventricular hypertrophy 0.8 2.9 5.3 9.0
History of myocardial infarction 3.5 9.7 3.4 6.4
History of heart failure 3.1 9.3 6.4 12.0
Hemostatic markers
 von Willebrand factor, % 111.3 (42.6) 124.5 (46.4) 132.4 (55.6) 148.9 (67.5)
 Factor VIII activity, % 125.0 (34.2) 133.9 (36.7) 146.4 (47.1) 158.9 (52.9)
 Fibrinogen, mg/dL 295.7 (61.0) 313.9 (64.2) 318.9 (71.7) 332.9 (76.9)
 Factor VII activity, % 119.5 (28.7) 119.1 (28.3) 118.1 (30.6) 120.1 (36.1)
 Antithrombin III, % 110.2 (21.0) 109.4 (20.8) 114.9 (23.1) 115.6 (24.3)
 Protein C, μg/mL 3.2 (0.6) 3.2 (0.6) 3.1 (0.6) 3.1 (0.6)
 aPTT, seconds 29.1 (2.9) 28.9 (3.0) 29.1 (3.2) 29.0 (3.4)
aPTT: activated partial thromboplastin time. Values refer to percent or mean (standard deviation)
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Table 3
Association of extreme levels of hemostatic markers with incidence of AF (hazard ratios and 95% confidence
intervals), ARIC, 1987–2005
Hazard ratio (95% confidence interval)
≥p90 vs <p90* ≥p95 vs <p95*
Von Willebrand factor
Model 1 1.54 (1.31–1.81) 1.67 (1.35–2.08)
Model 2 1.36 (1.15–1.60) 1.40 (1.12–1.74)
Model 3 1.33 (1.13–1.57) 1.36 (1.09–1.70)
Factor VIIIc
Model 1 1.56 (1.32–1.86) 1.63 (1.29–2.05)
Model 2 1.29 (1.08–1.54) 1.30 (1.03–1.64)
Model 3 1.27 (1.07–1.51) 1.29 (1.02–1.63)
Fibrinogen
Model 1 1.61 (1.36–1.90) 1.78 (1.43–2.21)
Model 2 1.19 (1.00–1.41) 1.28 (1.03–1.60)
Model 3 1.17 (0.98–1.38) 1.26 (1.01–1.58)
Factor VIIc*
Model 1 1.10 (0.91–1.32) 1.15 (0.89–1.47)
Model 2 1.19 (0.99–1.44) 1.25 (0.97–1.60)
Model 3 1.21 (1.01–1.47) 1.26 (0.98–1.62)
ATIII
Model 1 1.09 (0.90–1.32) 1.13 (0.88–1.46)
Model 2 1.00 (0.82–1.21) 1.01 (0.78–1.30)
Model 3 0.99 (0.81–1.20) 1.00 (0.77–1.29)
Protein C*
Model 1 1.11 (0.93–1.34) 1.31 (1.06–1.61)
Model 2 1.14 (0.94–1.38) 1.33 (1.07–1.65)
Model 3 1.12 (0.93–1.36) 1.29 (1.04–1.59)
aPTT
Model 1 0.92 (0.75–1.12) 0.96 (0.73–1.26)
Model 2 0.95 (0.78–1.16) 0.97 (0.73–1.27)
Model 3 0.94 (0.77–1.15) 0.96 (0.73–1.26)
aPTT: activated partial thromboplastin time; ATIII: antithrombin III
Model 1: Cox proportional hazards model adjusted for age, race, and gender
Model 2: As model 1, additionally adjusted for center, education, income, smoking, alcohol intake, sports-related physical activity, body mass
index, height, left ventricular hypertrophy, systolic blood pressure, use of antihypertensive medications, diabetes, cholesterol meds, HDL-
cholesterol, and total cholesterol
Model 3: As model 2, additionally adjusted for history of myocardial infarction or heart failure at baseline
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*
For protein C and factor VIIc, the exposed are defined as those with levels ≤10th (first column) and ≤5th (second column) percentiles.
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